Experienced in Liposarcoma

Dr. William W. Maclaughlin

Hematology Oncology | Hematology | Oncology
110 Wimbledon Sq, Suite E, 
Chesapeake, VA 
Accepting New Patients
Experienced in Liposarcoma
110 Wimbledon Sq, Suite E, 
Chesapeake, VA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

William Maclaughlin is a Hematologist Oncology specialist and a Hematologist in Chesapeake, Virginia. Dr. Maclaughlin is rated as an Experienced provider by MediFind in the treatment of Liposarcoma. His top areas of expertise are Pleuropulmonary Blastoma, Triple-Negative Breast Cancer, Febrile Neutropenia, and Myelodysplastic Syndrome (MDS). Dr. Maclaughlin is currently accepting new patients.

His clinical research consists of co-authoring 2 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in VA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
HealthKeepers
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Piedmont
  • HMO
  • POS
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 2 Less Insurance Carriers -

Locations

110 Wimbledon Sq, Suite E, Chesapeake, VA 23320

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2025
Intervention Type: Drug
Study Drugs: tucatinib, T-DM1
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 03, 2024
Intervention Type: Drug, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Paclitaxel
Study Phase: Phase 3
View 4 Less Clinical Trials

2 Total Publications

A prospective study to evaluate febrile neutropenia incidence in patients receiving pegfilgrastim on-body injector vs other choices.
A prospective study to evaluate febrile neutropenia incidence in patients receiving pegfilgrastim on-body injector vs other choices.
Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Published: January 13, 2022
Similar Doctors
Advanced in Liposarcoma
Dr. Daniel B. Aruch
Hematology Oncology | Pediatrics | Hematology
Advanced in Liposarcoma
Dr. Daniel B. Aruch
Hematology Oncology | Pediatrics | Hematology

Virginia Oncology Associates

1950 Glenn Mitchell Dr, Suite 102, 
Virginia Beach, VA 
 (8.5 miles away)
757-368-0437
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Daniel Aruch is a Hematologist Oncology specialist and a Pediatrics provider in Virginia Beach, Virginia. Dr. Aruch is rated as a Distinguished provider by MediFind in the treatment of Liposarcoma. His top areas of expertise are Paget Disease of the Breast, Familial Colorectal Cancer, Breast Cancer, Lung Cancer, and Splenectomy. Dr. Aruch is currently accepting new patients.

Advanced in Liposarcoma
Dr. Gauri V. Radkar
Hematology Oncology | Hematology | Oncology
Advanced in Liposarcoma
Dr. Gauri V. Radkar
Hematology Oncology | Hematology | Oncology

Virginia Oncology Associates

1950 Glenn Mitchell Dr, Suite 102, 
Virginia Beach, VA 
 (8.5 miles away)
757-368-0437
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Gauri Radkar is a Hematologist Oncology specialist and a Hematologist in Virginia Beach, Virginia. Dr. Radkar is rated as a Distinguished provider by MediFind in the treatment of Liposarcoma. Her top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Colorectal Cancer, and Familial Colorectal Cancer. Dr. Radkar is currently accepting new patients.

Advanced in Liposarcoma
Dr. Michael Lee
Hematology | Oncology
Advanced in Liposarcoma
Dr. Michael Lee
Hematology | Oncology

Virginia Oncology Associates

1950 Glenn Mitchell Dr, Suite 102, 
Virginia Beach, VA 
 (8.5 miles away)
757-368-0437
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Michael Lee is a Hematologist and an Oncologist in Virginia Beach, Virginia. Dr. Lee is rated as a Distinguished provider by MediFind in the treatment of Liposarcoma. His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Myelodysplastic Syndrome (MDS), and Anemia.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Maclaughlin's expertise for a condition
ConditionClose
      View All 7 Advanced Conditions
      View All 92 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile